Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients.
Sanfang TuLijuan ZhouRui HuangXuan ZhouJilong YangYanjie HeYuxing HuHonghao ZhangXiaoling XieYu-Hua LiPublished in: American journal of hematology (2024)
Keyphrases
- cell therapy
- dendritic cells
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- acute lymphoblastic leukemia
- stem cells
- prognostic factors
- peritoneal dialysis
- mesenchymal stem cells
- diffuse large b cell lymphoma
- regulatory t cells
- immune response
- hodgkin lymphoma
- young adults